What kind of drug is Olverembatinib?

Olverembatinib is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI). It is primarily indicated for the treatment of specific types of leukemia, particularly in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to conventional TKI therapies or harbor the T315I gene mutation.